Cargando…
Sustained viral response and relapse after discontinuation of oral antiviral drugs in HBeAg-positive patients with chronic hepatitis B infection
OBJECTIVE: To investigate the sustained virological response and relapse in chronic hepatitis B (CHB) patients with hepatitis B e antigen (HBeAg) positive after stopping oral antiviral drugs, and to monitor the disease progression and the incidence of adverse events such as liver cirrhosis and hepat...
Autores principales: | Sun, Fangfang, Li, Zhenhua, Hu, Leiping, Deng, Wen, Jiang, Tingting, Wang, Shiyu, Bi, Xiaoyue, Lu, Huihui, Yang, Liu, Lin, Yanjie, Zeng, Zhan, Shen, Ge, Liu, Ruyu, Chang, Min, Wu, Shuling, Gao, Yuanjiao, Hao, Hongxiao, Xu, Mengjiao, Chen, Xiaoxue, Zhang, Lu, Lu, Yao, Dong, Jianping, Xie, Yao, Li, Minghui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732422/ https://www.ncbi.nlm.nih.gov/pubmed/36505492 http://dx.doi.org/10.3389/fimmu.2022.1082091 |
Ejemplares similares
-
Study on pathological and clinical characteristics of chronic HBV infected patients with HBsAg positive, HBV DNA negative, HBeAg negative
por: Zeng, Zhan, et al.
Publicado: (2023) -
Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN α-2a therapy
por: Cao, Weihua, et al.
Publicado: (2022) -
A nomogram based on HBeAg, AST, and age to predict non-minimal liver inflammation in CHB patients with ALT <80 U/L
por: Zhang, Lu, et al.
Publicado: (2023) -
The relation of the frequency and functional molecules expression on plasmacytoid dendritic cells to postpartum hepatitis in women with HBeAg-positive chronic hepatitis B virus infection
por: Wang, Fuchuan, et al.
Publicado: (2022) -
Dynamic changes of cytokine profiles and virological markers during 48 weeks of entecavir treatment for HBeAg-positive chronic hepatitis B
por: Li, Minghui, et al.
Publicado: (2022)